

# Journal of Visualized Experiments

## Continuous Fluorescence-based Endonuclease-coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE62949R2
Full Title:	Continuous Fluorescence-based Endonuclease-coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Corresponding Author:	Rebecca Switzer, Ph.D. Bucknell University Lewisburg, PA UNITED STATES
Corresponding Author's Institution:	Bucknell University
Corresponding Author E-Mail:	r1f024@bucknell.edu
Order of Authors:	Rebecca Switzer, Ph.D. Katie Ward Jessica Medrano
Additional Information:	
Question	Response
Please specify the section of the submitted manuscript.	Biochemistry
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (\$1400)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	Lewisburg, Pennsylvania, United States of America
Please confirm that you have read and agree to the terms and conditions of the author license agreement that applies below:	I agree to the <a href="#">Author License Agreement</a>
Please provide any comments to the journal here.	
Please confirm that you have read and agree to the terms and conditions of the video release that applies below:	I agree to the <a href="#">Video Release</a>

**TITLE:**

Continuous Fluorescence-based Endonuclease-coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

**AUTHORS AND AFFILIATIONS:**

Rebecca L. Switzer<sup>1</sup>, Katie A. Ward<sup>2</sup>, Jessica Medrano<sup>2</sup>

<sup>1</sup>Department of Chemistry, Bucknell University, Lewisburg, PA, USA

<sup>2</sup>Program in Cell Biology/Biochemistry, Bucknell University, Lewisburg, PA, USA

**Email addresses of co-authors:**

Katie A. Ward (kaw032@bucknell.edu)

Jessica Medrano (jem057@bucknell.edu)

**Corresponding author:**

Rebecca L. Switzer (rlf024@bucknell.edu)

**SUMMARY:**

DNA methyltransferases are potential cancer drug targets. Here, a protocol is presented to assess small molecules for DNA methyltransferase inhibition. This assay utilizes an endonuclease to couple DNA methylation to fluorescence generation and allows for enzyme activity to be monitored in real time.

**ABSTRACT:**

DNA methylation, a form of epigenetic gene regulation, is important for normal cellular function. In cells, proteins called DNA methyltransferases (DNMTs) establish and maintain the DNA methylation pattern. Changes to the normal DNA methylation pattern are linked to cancer development and progression, making DNMTs potential cancer drug targets. Thus, identifying and characterizing novel small molecule inhibitors of these enzymes is of great importance. This paper presents a protocol that can be used to screen for DNA methyltransferase inhibitors. The continuous coupled kinetics assay allows for initial velocities of DNA methylation to be determined in the presence and absence of potential small molecule inhibitors. The assay uses the methyl-sensitive endonuclease *Gla I* to couple methylation of a hemimethylated DNA substrate to fluorescence generation.

This continuous assay allows for enzyme activity to be monitored in real time. Conducting the assay in small volumes in microtiter plates reduces the cost of reagents. Using this assay, a small example screen was conducted for inhibitors of DNMT1, the most abundant DNMT isozyme in humans. The highly substituted anthraquinone natural product, laccaic acid A, is a potent, DNA-competitive inhibitor of DNMT1. Here, we examine three potential small molecule inhibitors—anthraquinones or anthraquinone-like molecules with one to three substituents—at two concentrations to describe the assay protocol. Initial velocities are used to calculate the percent activity observed in the presence of each molecule. One of three compounds examined exhibits concentration-dependent inhibition of DNMT1 activity, indicating that it is a potential inhibitor

of DNMT1.

## INTRODUCTION:

DNA methylation is an important epigenetic mark that regulates gene expression and chromatin structure. Methylation occurs predominately in CpG dinucleotides—cytosine followed by guanosine; the methyl group is added to the 5-position of cytosine. Correct DNA methylation patterns, and thus proper gene expression, are needed for appropriate cellular development and function. Many disease states have been associated with changes to the normal methylation pattern<sup>1-3</sup>. For example, there is a link between cancer initiation and progression and alterations to the DNA methylation pattern. Typically, cancer cells exhibit lower overall levels of methylcytosine, which contributes to genome instability. At the same time, the methylcytosine that is present in the genome is concentrated in the promoter regions of tumor suppressor genes, which leads to gene silencing of these important proteins. Notably, epigenetic changes are dynamic and reversible, unlike the DNA mutations associated with tumorigenesis. This has made the proteins involved in epigenetic gene regulation interesting drug targets<sup>2,4</sup>.

DNA methyltransferases (DNMTs) are the proteins responsible for generating and maintaining DNA methylation patterns. Three catalytically active isozymes, DNMT1, DNMT3a, and DNMT3b, exist in humans. During development and differentiation, the *de novo* methyltransferases, DNMT3a and DNMT3b, establish methylation patterns. Both enzymes can bind the catalytically inactive DNMT3L protein to form complexes that exhibit increased activity<sup>1,5</sup>. Following cell division, daughter cells contain hemimethylated DNA—DNA containing methylcytosine in only one strand of the duplex—because the newly synthesized DNA is devoid of methylation marks. The major function of DNMT1 is to methylate this hemimethylated DNA, thus re-establishing the full methylation pattern<sup>1,5</sup>.

Links between DNMT activity and cancer are well established. Overexpression of DNMT1, either by transcriptional or post-translational mechanisms, is a consequence of several common oncogenic pathways<sup>6-9</sup>. Genetic approaches to lower DNMT1 activity using hypomorphic alleles result in decreased tumor formation in *Apc*<sup>(Min)</sup> mice<sup>10</sup>. Antisense oligonucleotides that knockdown *DNMT1* inhibit neoplasia in cell culture and mouse tumor models<sup>11,12</sup>. Thus, inhibiting DNMT1 activity seems like a promising cancer therapy approach. However, the roles the DNMT3 isozymes play are not so straightforward. *DNMT3a* mutations are found in acute myeloid leukemia<sup>13</sup> and myelodysplastic syndrome<sup>14</sup>. At least one of the identified mutations has been shown to decrease the DNA methylation activity of the enzyme<sup>15</sup>. However, DNMT3b is overexpressed in breast cancer<sup>16</sup> and colorectal cancer<sup>17</sup>. With the various DNMT isozymes playing different roles in carcinogenesis, identifying isozyme-specific inhibitors will be critical. Not only will these compounds be useful for the development of therapeutics, but isozyme-specific inhibitors would also be an invaluable tool to dissect the role of each DNMT isozyme in cancer etiology.

Several DNMT inhibitors have been reported in the literature. Known DNMT inhibitors can be divided into two classes: nucleoside and non-nucleoside. Nucleoside inhibitors are typically cytidine analogs. These compounds are incorporated into DNA and covalently trap DNMTs. 5-

azacytidine and 5-aza-2'-deoxycytidine have been approved for the treatment of myelodysplastic syndrome and acute myeloid leukemia<sup>4,18</sup>. The high toxicity, low bioavailability, and chemical instability of these compounds present problems. Ongoing work is examining the efficacy of the next generation of nucleoside inhibitors; SGI-110, derived from 5-aza-2'-deoxycytidine, is one example<sup>19,20</sup>. Nucleoside inhibitors are not isozyme-specific and will inactivate any DNMT isozyme encountered. Therefore, treatment with a nucleoside-demethylating agent results in the depletion of all DNMT isozymes<sup>4,18</sup>. Non-nucleoside inhibitors do not need to be incorporated into DNA to exert their inhibitory effects. Instead, these molecules bind directly to DNMTs, introducing the possibility for isozyme-specific inhibition. Several non-nucleoside inhibitors have been discovered to date, including SGI-1027<sup>21</sup>, hydralazine<sup>22</sup>, procainamide<sup>23</sup>, RG108 and derivatives<sup>24</sup>, and natural products, (-)-epigallocatechin 3-gallate (EGCG)<sup>25</sup> and laccaic acid A<sup>26,27</sup>. Most of the non-nucleoside inhibitors discovered to date are not isozyme-selective or display weak preferences for one DNMT isozyme. In addition, the potency of these molecules needs to be improved, especially in cells<sup>4,18</sup>. Thus, there is a need to discover or develop more potent, isozyme-selective DNMT inhibitors.

A hurdle to discovering new small molecule inhibitors of DNMTs is the laborious assays traditionally used to examine DNMT activity<sup>28</sup>. Assays are usually discontinuous with multiple steps. The enzymatic activity of DNMTs is still routinely assayed using radioactive S-adenosyl methionine (SAM)<sup>29-34</sup>. Non-radioactive assays for DNA methylation have been developed as well. For example, assays utilizing methyl-sensitive restriction endonucleases and electrophoresis to separate the digestion products have been described<sup>35,36</sup>. These types of discontinuous, multistep assays are not readily amenable to drug discovery. Since the mid-2000s, several DNA methylation assays with a higher throughput have been developed<sup>28</sup>. A scintillation proximity assay was used to screen for DNMT1 inhibitors<sup>37</sup>. Another assay utilizing a methyl-sensitive restriction endonuclease was used to screen for DNMT3a inhibitors<sup>25,38</sup>. While both assays allowed for higher throughput than traditional DNA methylation assays, the assays require multiple steps and do not allow the observation of methylation activity in real time. More recently, a continuous kinetics assay has been described that couples the formation of S-adenosylhomocysteine (SAH), one product of the methylation reaction, to the spectroscopic change at 340 nm associated with NADPH oxidation<sup>39</sup>. This assay utilizes three coupling enzymes to generate a spectroscopic signal.

We developed a fluorescence-based endonuclease-coupled DNA methylation assay that utilizes a single commercially available coupling enzyme and can generate data in real time (**Figure 1**). A hairpin oligonucleotide containing three methylcytosines is used as a substrate. The substrate DNA contains a fluorophore on the 3' end and a quencher on the 5' end. Methylation of the hemimethylated CpG site generates the cleavage site for the endonuclease Gla I—fully methylated GCGC. Gla I cleavage of the product oligonucleotide releases the fluorophore from the quencher and generates fluorescence in real time. The assay can be used to examine the activity of any isoform of DNMT; however, higher activity is observed with DNMT1 as this isozyme preferentially methylates hemimethylated DNA<sup>1,5</sup>. Even more robust activity is observed if the autoinhibitory Replication Foci Targeting Sequence (RFTS) domain is removed from DNMT1. This domain, found in the N-terminal regulatory region, binds to the catalytic site and prevents DNA

binding. Removal of the first ~600 amino acids results in a truncated enzyme that is significantly more active than the full-length enzyme (~640-fold increase in  $k_{cat}/K_m$ )<sup>40</sup>. This activated form of the enzyme, referred to as RFTS-lacking DNMT1 (amino acids 621–1616), allows for the easier identification of inhibitors due to its increased catalytic power. This paper presents a protocol to utilize RFTS-lacking DNMT1 in assays to screen for potential small molecule inhibitors. Using the endonuclease-coupled continuous assay, the initial velocity is determined in the presence and absence of a few small molecules. Each potential inhibitor is examined at two concentrations to look for concentration-dependent DNMT1 inhibition. The percent activity observed in the presence of the small molecules was calculated in each case.

[Place **Figure 1** here]

## PROTOCOL:

### 1. Prepare assay solutions for the screen

NOTE: The concentrations of substrates used in this assay can be adapted. For RFTS-lacking DNMT1, the experimentally determined  $K_m$  values for the hairpin DNA substrate and SAM are 1–2 nM and 2  $\mu$ M, respectively<sup>26,40</sup>.

#### 1.1. Prepare 600 $\mu$ L of each assay condition being tested in microcentrifuge tubes on ice.

NOTE: The total volume of assay solution needed depends on the number of replicates being conducted. Each assay condition was run in triplicate for this protocol.

1.1.1. Add ddH<sub>2</sub>O and 5x methylation buffer (250 mM Tris pH 7.5, 5 mM MgCl<sub>2</sub>, 500 mM potassium glutamate, 5 mM dithiothreitol (DTT), 25% glycerol) to each tube to achieve a final concentration of 1x buffer. For assays containing 20  $\mu$ M compound, add 472  $\mu$ L of ddH<sub>2</sub>O and 120  $\mu$ L 5x buffer. For assays containing 50  $\mu$ M compound, add 470  $\mu$ L of ddH<sub>2</sub>O and 120  $\mu$ L of 5x buffer.

1.1.2. Add 3.15  $\mu$ L of 20 mg/mL bovine serum albumin (BSA) to each sample.

1.1.3. Add 2  $\mu$ L of 3.15  $\mu$ M hairpin DNA substrate and 1.33  $\mu$ L of 4.75 mM SAM to each sample.

NOTE: The concentration of substrates in the assay solution mixture is 1.05x the desired final concentrations.

1.1.4. Add inhibitor to a final concentration of 21  $\mu$ M (1.26  $\mu$ L of 10 mM) or 52.5  $\mu$ M (3.15  $\mu$ L of 10 mM) to the appropriate samples. Add an equivalent amount of dimethylsulfoxide (DMSO) to a control sample.

NOTE: The concentration of inhibitor used in the screen can be varied. The maximum final DMSO concentration should be  $\leq$ 5% (v/v). DMSO concentrations up to 5% (v/v) have no effect on the

activity observed in the assay<sup>26</sup>.

1.2. Mix the solutions by vortexing (3,000 rpm) for 3 s. Spin the samples for a few seconds in a tabletop mini centrifuge ( $1,200 \times g$ ) to ensure that the solution is collected at the bottom of the tube.

1.3. Aliquot 95  $\mu\text{L}$  of each assay solution into 6 consecutive wells in a black half-area 96-well plate (**Figure 2**).

NOTE: These screening assays were performed in two batches. First, 20  $\mu\text{M}$  inhibitor samples (4 total conditions) were examined, followed by the 50  $\mu\text{M}$  inhibitor samples (4 total conditions).

[Place **Figure 2** here]

## 2. Prepare enzyme solutions for screen

NOTE: RFTS-lacking DNMT1 can be expressed in *E. coli* and purified to homogeneity. Expression and purification procedures for RFTS-lacking DNMT1 have been described previously<sup>41</sup>. The volume of enzyme needed depends on the number of assays being conducted. Here, four different assays are being performed in each set; each assay is completed in triplicate.

2.1. Prepare 75  $\mu\text{L}$  of each enzyme solution in microcentrifuge tubes on ice.

NOTE: Two enzyme solutions will be needed. One solution will contain DNMT1 and Gla I; the other will contain only Gla I.

2.1.1. Add ddH<sub>2</sub>O and 5x methylation buffer (250 mM Tris pH 7.5, 5 mM MgCl<sub>2</sub>, 500 mM potassium glutamate, 5 mM DTT, 25% glycerol) to each tube to achieve a final concentration of 1x buffer. For the Gla I enzyme solution, add 15  $\mu\text{L}$  of 5x buffer and 58.8  $\mu\text{L}$  ddH<sub>2</sub>O. For the DNMT1+Gla I enzyme solution, add 15  $\mu\text{L}$  of 5x buffer and 58.2  $\mu\text{L}$  ddH<sub>2</sub>O.

2.1.2. Add 1.2  $\mu\text{L}$  of 10 U/ $\mu\text{L}$  Gla I to each solution for a final concentration of 0.16 U/ $\mu\text{L}$ .

2.1.3. Add 0.6  $\mu\text{L}$  of 5  $\mu\text{M}$  RFTS-lacking DNMT1 for a final concentration of 40 nM to the DNMT1+Gla I solution.

2.2. Tap gently to mix the solutions. Spin the samples for a few seconds in a tabletop mini centrifuge ( $1,200 \times g$ ) to ensure that the solution is collected at the bottom of the tube.

2.3. Aliquot 12  $\mu\text{L}$  of each enzyme solution into 6 wells in a conical-bottomed 96-well plate (**Figure 3**).

[Place **Figure 3** here]

### 3. Run the assay and analyze the data.

3.1. Preheat the plate reader to 37 °C. Insert the black plate containing the assay solutions. Shake the plate (double orbital at 425 cpm for 5 s) and read the fluorescence with an excitation wavelength of 485 nm and an emission wavelength of 528 nm. Incubate the plate at 37 °C for 5 min.

NOTE: Alternatively, filters with proper wavelength cutoffs can be used for the fluorescence readings.

3.2. Remove the assay plate. Add 5 µL of enzyme solution to each well and mix by pipetting up and down.

NOTE: Use multichannel pipets so that a row of samples can be initiated simultaneously.

3.3. Insert the plate into the plate reader. Record fluorescence every 53 s for 30 min. Shake the plate (double orbital at 425 cpm for 4 s) before each reading.

3.4. Average triplicate Glc I control assays for each condition. Subtract the average Glc I-containing control reaction trace from the triplicate traces obtained in the presence of RFTS-lacking DNMT1. Determine the average and standard error of the mean for the corrected replicates.

3.5. Plot the average corrected reaction trace and fit the initial linear portion to a line to determine the initial velocity.

3.6. Determine the percent activity by dividing the velocity observed in the presence of a compound by the velocity observed in the DMSO-containing control reaction and multiplying by 100.

### 4. Additional assay control—sequential addition of enzymes

4.1. Prepare 550 µL of assay solution in a microcentrifuge tube on ice. Add 110 µL of 5x methylation buffer, 3.88 µL of 3.15 µM hairpin DNA substrate, 6.43 µL of 47.5 mM SAM, 3.06 µL of 20 mg/mL BSA, and 426.6 µL of ddH<sub>2</sub>O.

4.2. Mix the solution by vortexing (3,000 rpm) for 3 s. Spin the samples for a few seconds in a tabletop mini centrifuge (1,200 × g) to ensure that the solution is collected at the bottom of the tube.

4.3. Aliquot 90 µL of the assay solution into 6 consecutive wells in a black half-area 96-well plate.

4.4. Prepare the DNMT1 enzyme solutions on ice. Add 4 µL of 5x methylation buffer, 0.76 µL

of 5  $\mu$ M RFTS-lacking DNMT1, and 15.24  $\mu$ L of ddH<sub>2</sub>O to one tube. Add 4  $\mu$ L of 5x methylation buffer and 16  $\mu$ L of ddH<sub>2</sub>O to another tube.

4.5. Tap gently to mix the solutions. Spin the samples for a few seconds in a tabletop mini centrifuge (1,200  $\times$  *g*) to ensure that the solution is collected at the bottom of the tube.

4.6. Add 5  $\mu$ L of the DNMT1-containing solution to three wells in the black half-area 96-well plate. Add 5  $\mu$ L of the buffer control solution to the other three wells.

4.7. Place the microtiter plate into the plate reader preheated to 37  $^{\circ}$ C. Shake the plate (double orbital at 425 cpm for 3 s) and read the fluorescence with an excitation wavelength of 485 nm and an emission wavelength of 528 nm. Repeat the shake and read every 60 s for 30 min.

4.8. While the assay plate is in the plate reader, prepare the Gla I solution on ice. Add 8  $\mu$ L of 5x methylation buffer, 0.64  $\mu$ L of 10 U/ $\mu$ L Gla I, and 31.4  $\mu$ L of ddH<sub>2</sub>O to a microcentrifuge tube. Tap gently to mix the solution. Spin the sample for a few seconds in a tabletop mini centrifuge (1,200  $\times$  *g*) to ensure that the solution is collected at the bottom of the tube.

4.9. Aliquot 6  $\mu$ L of the Gla I solution into 6 wells in a conical-bottomed 96-well plate.

4.10. Following the initial 30 min read, remove the black plate from the plate reader. Add 5  $\mu$ L of Gla I solution to all 6 wells and mix by pipetting up and down.

NOTE: Use a multichannel pipet so that all wells can be initiated simultaneously.

4.11. Place the black plate back into the plate reader. Record fluorescence every 35 s for 35 min. Shake the plate (double orbital at 425 cpm for 3 s) before each reading.

#### REPRESENTATIVE RESULTS:

Active DNMT1 is a prerequisite for this analysis. RFTS-lacking DNMT1 was expressed in *E.coli* and purified to homogeneity following previously published procedures<sup>41</sup>. To ensure the purified enzyme was active, a discontinuous endonuclease-coupled assay was used to examine DNA methylation activity<sup>36</sup>. This assay utilizes a 32 base pair duplex DNA with a single hemimethylated CpG positioned in a Sau3A1 cleavage site. Sau3A1 can cleave the hemimethylated substrate DNA; however, cleavage is blocked when the DNA is fully methylated. RFTS-lacking DNMT1 was added to assays containing 1  $\mu$ M DNA and 0.5 mM SAM, and aliquots were removed and flash-frozen over 30 min. Samples were subsequently digested with Sau3A1, and the products were separated by gel electrophoresis. As shown in **Figure 4**, the DNA is protected from cleavage as the reaction time increases, indicating that RFTS-lacking DNMT1 is methylating the hemimethylated DNA. Most of the 1  $\mu$ M substrate DNA originally present in the assay has been converted to product over the 30-min time course.

The endonuclease-coupled assay described in this paper allows the observation of DNA methylation activity in real time as an increase in fluorescence. The key to the success of this



assay is the methyl sensitivity of the endonuclease Gla I. Gla I does not efficiently cleave the hemimethylated substrate DNA but will cleave the fully methylated product DNA (**Figure 1**). Cleavage of the hairpin DNA is required to release the fluorophore from the quencher and generate an increase in fluorescence. To demonstrate that the enzymes are working as expected, a control reaction was conducted in which the enzymes, RFTS-lacking DNMT1 and Gla I, were added sequentially rather than concurrently. If the coupled assay is working correctly, the addition of DNMT1 should not impact fluorescence, as methylation of the DNA substrate is not expected to impact the background fluorescence of the internally quenched hairpin DNA. However, subsequent addition of Gla I to assays that contained the methyltransferase should result in fluorescence generation due to cleavage of the fully methylated hairpin DNA. The hemimethylated hairpin DNA substrate itself does have background fluorescence (**Figure 5**); these assays contained 20 nM hairpin DNA and 500  $\mu$ M SAM. RFTS-lacking DNMT1 or buffer was added to the assays, and fluorescence was followed for 30 min.

As seen in **Figure 5**, the fluorescence is unaffected by the RFTS-lacking DNMT1 in the absence of the coupling enzyme (blue shades contained 10 nM RFTS-lacking DNMT1 while red shades are the buffer control). Thus, methylation of the hemimethylated CpG site by DNMT1 does not appreciably change the fluorescence signal. However, when Gla I was added to all wells, robust fluorescence generation was observed only in the assays that contained RFTS-lacking DNMT1 (**Figure 5**). This shows that methylation of the hemimethylated substrate DNA by DNMT1 is required for Gla I cleavage and the generation of fluorescence. It should be noted that the increase in fluorescence observed in this control assay reflects the activity of Gla I as the enzymes were added sequentially. Alternatively, these reaction mixtures could be digested with Gla I, and the resulting oligonucleotides could be separated by electrophoresis to visualize cleavage and ensure that the enzymes are working as expected.

To use this coupled assay to directly determine the initial velocities of DNMT1, both enzymes, RFTS-lacking DNMT1 and Gla I, need to be added simultaneously. As long as the rate of Gla I cleavage of the product DNA is faster than the rate of DNA methylation by DNMT1, the fluorescence signal generated will reflect DNA methylation activity. To ensure that DNMT1 activity is rate-limiting, the concentration of DNMT1 can be varied while holding all other assay conditions constant. The rate of fluorescence generation should be proportional to the concentration of DNMT1. This has previously been shown for RFTS-lacking DNMT1 under the conditions utilized here<sup>40</sup>. When utilizing this coupled assay to examine DNMT activity, a Gla I-containing control reaction is performed in addition to the reaction that contains both DNMT1 and Gla I (**Figure 6A**). The Gla I control has several functions. Subtracting the Gla I control reaction trace from the DNMT-containing reaction trace allows for the accounting of both slow cleavage of the hemimethylated DNA substrate and the background fluorescence. The corrected reaction traces generated reflect the DNA methylation activity of DNMT1. Fitting the initial linear portion of the corrected reaction trace allows for the determination of the initial velocity (**Figure 6B**). With 10 nM hairpin DNA substrate and 10  $\mu$ M SAM, an initial velocity of  $113 \pm 2$  RFU/min was obtained.

Substituted anthraquinones have previously been shown to inhibit the activity of DNMT1. The

natural product, laccaic acid A, a highly substituted anthraquinone, is a potent, DNA-competitive inhibitor of DNMT1<sup>27</sup>. A few compounds with simpler structures, one or two substituents on the anthraquinone core, with one being a bulky aromatic substituent, have also been shown to inhibit DNMT1 in a DNA-competitive manner<sup>41</sup>. Here, the ability of three substituted anthraquinones or anthraquinone-like molecules to inhibit RFTS-lacking DNMT1 activity in the Glc I-coupled assay was examined as an example of how to conduct these screening assays. These compounds contained one to three substituents, all on one side of the anthraquinone core (**Table 1**). The substrate concentrations (10 nM DNA and 10  $\mu$ M SAM) used for these assays are  $\sim$ 5x higher than the  $K_m$  for each substrate. The signal generated in the assay comes directly from the substrate DNA. Because of this, it is difficult to assay at concentrations near or below  $K_m$ ; there is simply not enough signal to detect. These substrate concentrations were chosen because robust activity is seen under these conditions in the absence of inhibitors (**Figure 6B**). Other substrate concentrations could be used in screening assays. For example, conducting a screen at saturating SAM concentrations could be used as a strategy to bias the search against SAM-competitive inhibitors.

Each assay contained the hairpin DNA substrate, the methyl-donating co-factor SAM, and a potential inhibitor or DMSO as a control for the screen. We routinely generate 10 mM solutions of screening compounds in DMSO for use in assays. Anthraquinones such as those examined here exhibit poor solubility in aqueous solutions. Thus, to generate concentrated stocks, DMSO is used as a solvent. The addition of DMSO up to 5% (v/v) final concentration does not impact activity in the assay<sup>26</sup>. However, when dealing with compounds with low solubility in aqueous solution, care should be taken to ensure that the compound is soluble at the chosen final screening concentration(s).

For each condition examined in the screen, a Glc I-containing control assay is performed. In addition to accounting for background fluorescence and slow cleavage of the substrate hairpin DNA, this control allows the determination of whether the potential inhibitor interferes with the spectroscopic signal (*e.g.*, it is fluorescent). After initiating the reaction by adding enzymes, fluorescence was measured for 30 min with a time interval of 53 s in the screening data. This is the fastest time interval available on the plate reader in this laboratory when reading an entire 96-well plate. Other time intervals could be used to generate the reaction traces. An appropriate time interval will depend on the instrument being utilized and the number of wells being read. To ensure reproducibility, each assay is conducted in triplicate. The average Glc I-containing control trace is subtracted from the reaction traces observed in the presence of RFTS-lacking DNMT1. The initial velocity of the reaction can be determined by fitting the initial linear portion of the corrected reaction traces.

Initially, the impact of three potential inhibitors on fluorescence generation was examined at a final concentration of 20  $\mu$ M. Higher concentrations of the potential inhibitors were chosen for screening for two reasons. First, the substrate concentrations in the assay are both above their respective  $K_m$  values. This can make it more difficult to detect inhibition in kinetics assays, particularly if the inhibitors are competitive. Second, the anthraquinone-like compounds used in this screen are significantly simpler in structure than the known inhibitor, laccaic acid A. As these

molecules contain only a few substituents around the core structure, we anticipated weaker interactions. In the DMSO-containing control assay, an initial velocity of  $111 \pm 5$  RFU/min was obtained (**Figure 7A**). Note, this is very similar to the rate reported earlier in the absence of DMSO and confirms that the addition of low amounts of DMSO does not impact the observed activity. The addition of two compounds decreased the observed initial velocity, while the addition of the third compound had no effect on activity. The initial velocities were used to determine the percent activity observed in the presence of each compound. At 20  $\mu$ M, the addition of compounds 1 and 2 resulted in a percent activity of  $\sim 80\%$ , while 100% percent activity was observed in the presence of compound 3, indicating that this molecule does not inhibit the enzyme (**Table 1**).

Inhibitors are expected to exhibit concentration-dependent inhibition. Next, these molecules were re-examined at an even higher concentration of 50  $\mu$ M. For this set of assays, the DMSO-containing control assay had an initial velocity of  $125 \pm 7$  RFU/min (**Figure 7B**). This velocity is slightly higher than the previously determined rates; however, these velocities are all relatively close within error. Again, compound 3 had little effect on the initial velocity, while the addition of compounds 1 and 2 decreased the observed initial velocity. As expected, at the higher concentration, compound 1 had a larger impact on activity. At 50  $\mu$ M, the addition of compound 1 resulted in a percent activity of  $\sim 60\%$  (**Table 1**). However, the addition of a higher concentration of compound 2 did not result in more robust inhibition. The percent activity observed in the presence of 50  $\mu$ M of compound 2 was again near 80%.

As can be seen in the data presented, the endonuclease-coupled fluorescence-based DNA methylation assay can be used to screen for potential DNMT inhibitors. The data indicate that compound 1 and compound 2 are potential inhibitors, while compound 3 is not. Additional studies are required to validate the potential inhibitors as true DNMT1 inhibitors.

#### FIGURE AND TABLE LEGENDS:

**Figure 1: DNA methylation assay.** A hemimethylated hairpin DNA with a fluorophore on the 5' end and a quencher on the 3' end is used as a substrate. DNMT1 catalyzes the transfer of the methyl group from *S*-adenosylmethionine to the nonmethylated CpG site, generating *S*-adenosylhomocysteine and fully methylated DNA. The DNA product contains the cleavage site for the endonuclease *Gla* I, which cleaves fully methylated GCGC sites. Cleavage of the product DNA releases the 5' fluorophore from the 3' quencher, generating fluorescence. Abbreviations: Fl = fluorophore; Q = quencher; DNMT1 = DNA methyltransferase 1; SAM = *S*-adenosylmethionine; SAH = *S*-adenosylhomocysteine.

**Figure 2: Assay plate setup.** Each assay solution is aliquoted into six wells in the black 96-well plate: DMSO control (blue), compound 1 (green), compound 2 (red), and compound 3 (yellow). Both RFTS-lacking DNMT1 and *Gla* I will be added to three wells. As a control, *Gla* I alone will be added to the other three wells. Abbreviations: RFTS = Replication Foci Targeting Sequence; DNMT1 = DNA methyltransferase 1; DMSO = dimethylsulfoxide.

**Figure 3: Enzyme plate setup.** The *Gla* I (grey) and DNMT1+*Gla* I (blue) solutions are each

aliquoted into six wells in the 96-well plate. Using a multichannel pipet, the enzyme can be added to a row of assay solutions simultaneously. For each assay condition (six wells), three wells will receive DNMT1+Gla I, and three wells will receive Gla I alone. Abbreviation: DNMT1 = DNA methyltransferase 1.

**Figure 4: DNMT1 activity control.** Hemimethylated duplex DNA methylation protects against Sau3A1 cleavage. RFTS-lacking DNMT1 was added to assay mixtures containing 1  $\mu$ M DNA and 500  $\mu$ M SAM. Samples were collected at the indicated time points during a 30-min incubation at 37 °C, digested with Sau3A1, and resolved by gel electrophoresis on 18% PAGE. Here, 5, 10, 15, and 30 min samples are shown. The first lane is a control lacking DNMT1. Abbreviations: DNMT1 = DNA methyltransferase 1; RFTS = Replication Foci Targeting Sequence.

**Figure 5: Fluorescence-based assay control.** RFTS-lacking DNMT1 (10 nM final concentration) and Gla I (0.8 U) were added sequentially to triplicate assays containing 20 nM hairpin DNA substrate and 500  $\mu$ M SAM. Addition of DNMT1 (blue circles) or buffer (red circles) alone had no effect on background fluorescence. Addition of Gla I to all assays results in fluorescence generation in assays that contained DNMT1, but not in assays that do not. Abbreviations: DNMT1 = DNA methyltransferase 1; RFTS = Replication Foci Targeting Sequence; RFU = relative fluorescence units.

**Figure 6: Fluorescence reaction traces.** Triplicate assays contained 10 nM hairpin DNA substrate and 10  $\mu$ M SAM. (A) RFTS-lacking DNMT1 (2 nM) and Gla I (0.8 U) were added to three assays (blue), and Gla I (0.8 U) alone was added to three assays (red). Robust fluorescence generation is observed only in the assays that contain both enzymes. (B) The average Gla I reaction trace was subtracted from the DNMT1+Gla I reaction traces. The average and standard error of the mean of the triplicate data are shown. Fitting the linear portion of the trace gives an initial velocity of  $113 \pm 2$  RFU/min. Abbreviations: DNMT1 = DNA methyltransferase 1; RFTS = Replication Foci Targeting Sequence; RFU = relative fluorescence units; SAM = S-adenosylmethionine.

**Figure 7: DNA methylation activity in the presence of potential inhibitors.** DNA methylation activity of RFTS-lacking DNMT1 was examined in the presence of DMSO (black), compound 1 (red), compound 2 (blue), or compound 3 (green). Corrected reaction traces at 20  $\mu$ M compound (A) and 50  $\mu$ M compound (B) were fit to determine the initial velocity. Addition of compounds 1 and 2 decreased the observed velocity, while compound 3 had little impact on activity. Average and standard error of the mean for the triplicate assays are shown. Abbreviations: DNMT1 = DNA methyltransferase 1; RFTS = Replication Foci Targeting Sequence; RFU = relative fluorescence units; DMSO = dimethylsulfoxide.

**Table 1: Initial velocities and percent activities observed in the presence of potential small molecule inhibitors.** Initial velocity was determined by fitting the initial linear portion of corrected reaction traces to a line; the error associated with the fit is reported. Percent activity was determined by dividing the rate determined in the presence of compound by the rate determined in the DMSO control reaction and multiplying by 100; associated error was propagated. Abbreviations: Cmpd = compound; DMSO = dimethylsulfoxide; RFU = relative

fluorescence units.

## DISCUSSION:

To identify and characterize inhibitors of DNA methyltransferases, the activity of the enzyme must be measured. Several methods for examining DNA methyltransferase activity exist. Activity is commonly monitored using radioactivity; transfer of the labeled methyl group of SAM can be quantified<sup>29-34</sup>. Gel-based assays that utilize methyl-sensitive endonucleases have also been described<sup>35,36</sup>. These assays are usually discontinuous and require multiple steps to examine activity. Here, an endonuclease-coupled DNA methylation assay is described to screen for potential DNA methyltransferase inhibitors. This technique has several advantages. The assay is relatively simple. It does not require separation techniques (*e.g.*, electrophoresis, filter binding) to obtain a signal. In addition, the assay is continuous, allowing the collection of data in real time. A different continuous kinetics assay for methylation activity was recently described<sup>39</sup>. However, this assay requires three coupling enzymes to generate a spectroscopic signal. The assay described here requires a single coupling enzyme.

These DNMT activity assays are performed by first generating an assay solution that contains all the assay components except the enzymes. The assay solutions contain the substrates, hairpin DNA and SAM; 0.1 mg/mL BSA is also routinely included in the assays. With the extremely low concentrations (in the nanomolar range) of DNA and DNMT1 used in the assay, the BSA increases the general protein concentration to help prevent adhesion to pipet tips, tubes, and microtiter plates and environmental insults that might impact enzyme activity. The reaction is then initiated by adding enzymes to the assay solutions. These dilutions must be accounted for when determining the final concentrations of all assay components. Reactions are initiated by adding 5  $\mu$ L of enzyme solution to 95  $\mu$ L of assay solution. Therefore, the concentrations of DNA, SAM, and BSA in the assay solutions are 1.05x the desired final concentration. For example, if 10 nM DNA is desired, assay solutions are generated with 10.5 nM DNA. The concentration of RFTS-lacking DNMT1 in the enzyme solution is 20x the desired final concentration. Here, 40 nM RFTS-lacking DNMT1 was used in the enzyme solution so that the final concentration of DNMT1 in each assay was 2 nM.

As Gla I is a commercially available enzyme, its quantity is given in units (U) as provided by the manufacturer. The enzyme solutions generated contain 0.16 U/ $\mu$ L Gla I so that a total of 0.8 U of Gla I is added to each well. To save on reagent costs, small volumes of the appropriate enzyme solutions are prepared, and those solutions are then aliquoted into conical-bottomed 96-well plates. Using multichannel pipets, 5  $\mu$ L of enzyme solutions are transferred from the conical-bottomed plate to the assay solutions in the black 96-well half-area plate. This process allows for a row of assays to be initiated simultaneously. Alternatively, with a different assay plate setup, enzyme solutions could be placed in reagent reservoirs, and then multichannel pipets could be used to add enzyme to the assay solutions. However, this approach will require higher volumes of enzyme solution due to liquid recovery waste in the reservoirs. We perform the assays in 96-well half-area plates; the smaller well size in these plates allows for a smaller total assay volume (100  $\mu$ L) than traditional 96-well plates, again saving on reagent costs.

The DNA methylation assay described here requires a hemimethylated substrate DNA due to the specificity of the coupling endonuclease *Gla* I. This makes the assay especially good for examining the activity of DNMT1, as this isozyme preferentially methylates hemimethylated DNA<sup>1</sup>. The DNMT3 isozymes do not exhibit a preference between nonmethylated and hemimethylated DNA<sup>1</sup>. Thus, this assay can be used to examine the activity of the DNMT3 isozymes as well. In fact, inhibition of DNMT3a by small molecules has been assessed using this assay<sup>26,27,41</sup>. The requirement of a hemimethylated substrate DNA means this assay cannot be used to examine substrate specificity or preference between nonmethylated and hemimethylated CpG sites.

This assay relies on a spectroscopic signal: the increase in fluorescence when the fluorophore and quencher are separated. Thus, small molecules that themselves fluoresce or quench fluorescence can interfere with the assay. One reason to conduct the *Gla* I-containing control for each assay condition is to check for this possibility. The spectroscopic properties of the small molecule could be accounted for simply by using the *Gla* I control data (*e.g.*, if the molecule has a weak fluorescence signal). However, if the molecule is strongly fluorescent or a strong quencher, this assay cannot be used to detect DNA methylation activity.

The screen described here is an initial assay to detect potential DNMT inhibitors. Compounds that are “hits” in the initial screen must be validated in secondary assays to ensure they are true DNMT inhibitors. Because this assay is a coupled kinetics assay, simply observing a decrease in fluorescence generation in the presence of a particular small molecule does not necessarily mean that the compound is inhibiting the methyltransferase. A small molecule capable of inhibiting the coupling enzyme *Gla* I would also result in an observed decrease in fluorescence generation. A simple secondary screen involves determining the activity of *Gla* I in the presence and absence of the potential inhibitors. For this assay, the fully methylated internally quenched hairpin DNA is used as a substrate<sup>26,41</sup>. Additional assays designed to examine aggregation-dependent inhibition and DNA intercalation can also be used as secondary assays to further validate potential inhibitors<sup>26,41</sup>. In the data presented here, compound 1 and compound 2 were identified as potential DNMT1 inhibitors. Using a variety of secondary assays, compound 1 has been validated as a direct inhibitor of DNMT1<sup>41</sup>. This work showed that compounds containing bulky substituents at the C2 position of the anthraquinone core seemed to be more effective inhibitors of DNMT1. However, more studies are needed to fully understand the structural determinants for DNMT1 inhibition.

The coupled assay described here has several potential uses. The assay can be utilized for steady-state kinetics experiments. Because the assay is continuous, determining initial velocities is straightforward. This assay has previously been used to examine macroscopic kinetics parameters (*i.e.*,  $K_m$ ,  $V_{max}$ , and  $k_{cat}$ ) of various truncated DNMT1 proteins<sup>40</sup>. The assay has been used to examine a small set of molecules for DNMT1 inhibition<sup>41</sup> and assess isozyme specificity of identified inhibitors by examining their impact on DNMT3a activity<sup>26,27,41</sup>. The assay has also been used to characterize inhibitors. The mechanism of inhibition and potency (*e.g.*,  $K_i$ ,  $IC_{50}$ ) of both inhibitory protein domains<sup>36,40</sup> and novel small molecules<sup>27,41</sup> have been determined using this coupled kinetics assay. The assay has also been adapted for use in an HTS campaign. In this case, the assay was miniaturized further to a 384-well format and used as an endpoint assay for

the initial screen<sup>26</sup>. Thus, the fluorescence-based endonuclease-coupled DNA methylation assay described here is a versatile assay that can be used to examine the activity of DNA methyltransferases and allows for the identification and characterization of small molecule inhibitors of these important epigenetic modifiers.

#### ACKNOWLEDGMENTS:

The authors thank Bucknell University and the Department of Chemistry for their support of this work.

#### DISCLOSURES:

The authors have no conflicts of interest to disclose.

#### REFERENCES:

- [1] Jurkowska, R. Z., Jurkowski, T. P., Jeltsch, A. Structure and function of mammalian DNA methyltransferases. *Chembiochem.* **12** (2), 206–222 (2011).
- [2] Hamidi, T., Singh, A. K., Chen, T. Genetic alterations of DNA methylation machinery in human diseases. *Epigenomics.* **7** (2), 247–265 (2015).
- [3] Norvil, A. B., Saha, D., Dar, M. S., Gowher, H. Effect of disease-associated germline mutations on structure function relationship of DNA methyltransferases. *Genes.* **10** (5), 369 (2019).
- [4] Foulks, J. M. et al. Epigenetic drug discovery: targeting DNA methyltransferases. *Journal of Biomolecular Screening.* **17** (1), 2–17 (2012).
- [5] Goll, M. G., Bestor, T. H. Eukaryotic cytosine methyltransferases. *Annual Review of Biochemistry.* **74**, 481–514 (2005).
- [6] Bigey, P., Ramchandani, S., Theberge, J., Araujo, F. D., Szyf, M. Transcriptional regulation of the human DNA Methyltransferase (*dnmt1*) gene. *Gene.* **242** (1–2), 407–418 (2000).
- [7] Detich, N., Ramchandani, S., Szyf, M. A conserved 3'-untranslated element mediates growth regulation of DNA methyltransferase 1 and inhibits its transforming activity. *Journal of Biological Chemistry.* **276** (27), 24881–24890 (2001).
- [8] MacLeod, A. R., Rouleau, J., Szyf, M. Regulation of DNA methylation by the Ras signaling pathway. *Journal of Biological Chemistry.* **270** (19), 11327–11337 (1995).
- [9] Slack, A., Cervoni, N., Pinard, M., Szyf, M. DNA methyltransferase is a downstream effector of cellular transformation triggered by simian virus 40 large T antigen. *Journal of Biological Chemistry.* **274** (15), 10105–10112 (1999).
- [10] Eads, C. A., Nickel, A. E., Laird, P. W. Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic mice. *Cancer Research.* **62**, 1296–1299 (2002).
- [11] MacLeod, A. R., and Szyf, M. Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis. *Journal of Biological Chemistry.* **270** (14), 8037–8043 (1995).
- [12] Ramchandani, S., MacLeod, A. R., Pinard, M., von Hofe, E., Szyf, M. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. *Proceedings of the National Academy Sciences of the United States of America.* **94** (2), 684–689 (1997).
- [13] Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. *New England Journal of*

617 *Medicine*. **363**, 2424–2433 (2010).

618 [14] Walter, M. J. et al. Recurrent *DNMT3A* mutations in patients with myelodysplastic  
619 syndromes. *Leukemia*. **25** (7), 1153–1158 (2011).

620 [15] Russler-Germain, D. A. et al. The R882H *DNMT3A* mutation associated with AML dominantly  
621 inhibits wild-type *DNMT3A* by blocking its ability to form active tetramers. *Cancer Cell*. **25** (4),  
622 442–454 (2014).

623 [16] Roll, J. D., Rivenbark, A. G., Jones, W. D., Coleman, W. B. *DNMT3b* overexpression contributes  
624 to a hypermethylator phenotype in human breast cancer cell lines. *Molecular Cancer*. **7**, 15  
625 (2008).

626 [17] Nosh, K. et al. *DNMT3B* expression might contribute to CpG island methylator phenotype  
627 in colorectal cancer. *Clinical Cancer Research*. **15** (11), 3663–3671 (2009).

628 [18] Erdmann, A., Halby, L., Fahy, J., Arimondo, P. B. Targeting DNA methylation with small  
629 molecules: what's next? *Journal of Medicinal Chemistry*. **58** (6), 2569–2583 (2015).

630 [19] Chuang, J. C. et al. S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective  
631 DNA methylation inhibitor in vivo and can reduce tumor growth. *Molecular Cancer Therapeutics*.  
632 **9** (5), 1443–1450 (2010).

633 [20] Issa, J. J. et al. Safety and tolerability of guadecitabine (SGI-110) in patients with  
634 myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-  
635 escalation phase 1 study. *Lancet Oncology*. **16** (9), 1099–1110 (2015).

636 [21] Datta, J. et al. A new class of quinoline-based DNA hypomethylating agents reactivates tumor  
637 suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation.  
638 *Cancer Research*. **69** (10), 4277–4285 (2009).

639 [22] Zambrano, P. et al. A phase I study of hydralazine to demethylate and reactivate the  
640 expression of tumor suppressor genes. *BMC Cancer*. **5**, 44 (2005).

641 [23] Lee, B. H., Yegnasubramanian, S., Lin, X., Nelson, W. G. Procainamide is a specific inhibitor of  
642 DNA methyltransferase 1. *Journal of Biological Chemistry*. **280** (49), 40749–40756 (2005).

643 [24] Asgatay, S. et al. Synthesis and evaluation of analogues of N-phthaloyl-L-tryptophan (RG108)  
644 as inhibitors of DNA methyltransferase 1. *Journal of Medicinal Chemistry*. **57** (2), 421–434 (2014).

645 [25] Ceccaldi, A. et al. C5-DNA methyltransferase inhibitors: from screening to effects on  
646 zebrafish embryo development. *Chembiochem*. **12** (9), 1337–1345 (2011).

647 [26] Fagan, R. L., Wu, M., Chédin, F., Brenner, C. An ultrasensitive high throughput screen for DNA  
648 methyltransferase 1-targeted molecular probes. *PLoS One*. **8** (11), e78752 (2013).

649 [27] Fagan, R. L., Cryderman, D. E., Kopelovich, L., Wallrath, L. L., Brenner, C. Laccic acid A is a  
650 direct, DNA-competitive inhibitor of DNA methyltransferase 1. *Journal of Biological Chemistry*.  
651 **288** (33), 23858–23867 (2013).

652 [28] Eglén, R. M., Reisine, T. Screening for compounds that modulate epigenetic regulation of the  
653 transcriptome: an overview. *Journal of Biomolecular Screening*. **16** (10), 1137–1152 (2011).

654 [29] Holz-Schietinger, C., Matje, D. M., Reich, N. O. Mutations in DNA methyltransferase  
655 (*DNMT3A*) observed in acute myeloid leukemia patients disrupt processive methylation. *Journal*  
656 *of Biological Chemistry*. **287** (37), 30941–30951 (2012).

657 [30] Norvil, A. B. et al. *Dnmt3b* methylates DNA by a noncooperative mechanism, and its activity  
658 is unaffected by manipulations at the predicted dimer interface. *Biochemistry*. **57** (29), 4312–  
659 4324 (2018).

660 [31] Bashtrykov, P., Ragozin, S., Jeltsch, A. Mechanistic details of the DNA recognition by the



Dnmt1 DNA methyltransferase. *FEBS Letters*. **586** (13), 1821–1823 (2012).

[32] Bashtrykov, P. et al. Targeted mutagenesis results in an activation of DNA methyltransferase 1 and confirms an autoinhibitory role of its RFTS domain. *Chembiochem*. **15** (5), 743–748 (2014).

[33] Berkyurek, A. C. et al. The DNA methyltransferase Dnmt1 directly interacts with the SET and RING finger-associated (SRA) domain of the multifunctional protein Uhrf1 to facilitate accession of the catalytic center to hemi-methylated DNA. *Journal of Biological Chemistry*. **289** (1), 379–386 (2014).

[34] Kanada, K., Takeshita, K., Suetake, I., Tajima, S., Nakagawa, A. Conserved threonine 1505 in the catalytic domain stabilizes mouse DNA methyltransferase 1. *Journal of Biochemistry*. **162** (4), 271–278 (2017).

[35] Bashtrykov, P. et al. Specificity of Dnmt1 for methylation of hemimethylated CpG sites resides in its catalytic domain. *Chemistry & Biology*. **19** (5), 572–578 (2012).

[36] Dolen, E. K., McGinnis, J. H., Tavory, R. N., Weiss, J. A., Switzer, R. L. Disease-associated mutations G589A and V590F relieve replication focus targeting sequence-mediated autoinhibition of DNA methyltransferase 1. *Biochemistry*. **58** (51), 5151–5159 (2019).

[37] Kilgore, J. A. et al. Identification of DNMT1 selective antagonists using a novel scintillation proximity assay. *Journal of Biological Chemistry*. **288** (27), 19673–19684 (2013).

[38] Ceccaldi, A. et al. Identification of novel inhibitors of DNA methylation by screening of a chemical library. *ACS Chemical Biology*. **8** (3), 543–548 (2013).

[39] Duchin, S., Vershinin, Z., Levy, D., Aharoni, A. A continuous kinetic assay for protein and DNA methyltransferase enzymatic activities. *Epigenetics & Chromatin*. **8**, 56 (2015).

[40] Syeda, F. et al. The replication focus targeting sequence (RFTS) domain is a DNA-competitive inhibitor of Dnmt1. *Journal of Biological Chemistry*. **286** (17), 15344–15351 (2011).

[41] Switzer, R. L., Medrano, J., Reedel, D. A., Weiss, J. Substituted anthraquinones represent a potential scaffold for DNA methyltransferase 1-specific inhibitors. *PLoS One*. **14** (7), e0219830 (2019).

Figure 1





Figure 2

[Click here to access/download;Figure;Figure 2.pdf](#) 

Condition 1

Condition 2



Condition 3

Condition 4








Figure 4


[Click here to access/download;Figure;Figure 4.pdf](#)






**A****B**




A



B





20 $\mu$ M		
	Initial Velocity (RFU/min)	Percent Activity
DMSO	111 $\pm$ 5	-
 Cmpd 1	88 $\pm$ 8	79 $\pm$ 8
 Cmpd 2	86 $\pm$ 6	77 $\pm$ 6
 Cmpd 3	111 $\pm$ 4	100 $\pm$ 6

50  $\mu$ M

Initial Velocity (RFU/min) Percent Activity

125  $\pm$  7

-

74  $\pm$  4

59  $\pm$  5

95  $\pm$  5

76  $\pm$  6

123  $\pm$  7

98  $\pm$  8



## Response to Reviews

The manuscript (JoVE62949) has been edited and expanded to address the comments expressed in the edited manuscript. We believe the manuscript is significantly stronger following both revisions. Please find individual comments below.

- Centrifugation speeds were added to the protocol section where indicated.
- We added the data and text explaining the discontinuous gel-based assay utilized to show RFTS-lacking DNMT1 is active to the paper. The data can be seen in the new Figure 4. A new figure legend has been added to explain the data in Figure 4. The remaining figures have been re-numbered to reflect the insertion of the new figure.
- The legend for Figure 2 has been edited to show where each condition was placed in the assay plate.
- Text was added in the discussion to say BSA helped prevent adhesion to tips, microtiter plates, etc.
- Additional small edits were made to the text for clarity. These are highlighted in the “track changes” in the Word document.